All In Biotech

Drug Trial Radar · NCT07589244

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

A Multicenter, Open-label Phase II/III Clinical Trial of VRT106 in Combination With Camrelizumab and Apatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Immune Checkpoint Inhibitor Therapy

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

May 13, 2026

Primary completion

Dec 31, 2028

Study completion Jun 30, 2029

Sponsor

Sponsor type
Industry
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

Conditions

  • HCC

Interventions

  • VRT106Drug

    VRT106,Intravenous infusion

  • VRT106 in combination with camrelizumab and apatinibDrug

    VRT106: Intravenous infusion Camrelizumab: Intravenous infusion Apatinib: Oral administration

  • Investigator's Choice of Standard of CareDrug

    At the investigator's discretion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose-Limiting ToxicitiesTime frame: Dose-limiting toxicity (DLT) will be assessed within 56 days following the first administration of VRT106.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.